Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPLANADE: Fluvastatin Added to ACEi and ATA in Chronic Nephropathies
NCT00199927Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Mar 2003
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fluvastatin in chronic kidney disease (CKD) and proteinuria (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: 24-hour urinary protein excretion rate at 6 months. Started Mar 2003; status: completed.
02
Drugs
fluvastatin
03
Conditions
chronic kidney disease (CKD)proteinuria
Beyond the preview
Go deeper on NCT00199927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00199927.